Scientists from the University of California have discovered theoretically targetable mutations in a breast cancer patient, using whole genome sequencing. The researchers used data on more than 10,000 patients with advanced breast cancer, and found that they could identify which genetic changes were responsible for each patient’s disease. The patient is suffering from ER-positive/HER2-negative metastatic breast cancer. The group's findings were published in the Cancer Research journal.
Scientists from the University of California have discovered theoretically targetable mutations in a breast cancer patient, using whole genome sequencing. The team were able to isolate and study the 61-year-old patient's liquid biopsies at two stages of her treatment, using only five circulating tumor cells at a time, due to the prohibitive cost of larger batches. The patient is suffering from ER-positive/HER2-negative metastatic breast cancer. The group's findings were published in the Cancer Research journal.